Yuan Zhe, Tam Vincent H
Chongqing Medical University, The First Affiliated Hospital, Department of Infectious Diseases, Chongqing 400016, China.
Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661.
There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent.
To review what is known about polymyxin B and to identify missing information or gaps for future investigations.
Pertinent information was reviewed from published literature in English.
RESULTS/CONCLUSION: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.
由于多重耐药革兰氏阴性菌的出现，多粘菌素B作为一种最后的治疗选择重新受到关注。尽管该药物已临床应用数十年，但人们对其许多方面的了解仍然非常有限。
回顾关于多粘菌素B的已知信息，并确定未来研究中缺失的信息或空白。
从英文发表的文献中回顾相关信息。
结果/结论：为了最佳使用多粘菌素B，需要更全面地了解标准化药敏试验、血清和组织中达到的浓度、多粘菌素B与其他药物联合使用时的抗菌活性以及耐药机制。还需要更精确地描述药物浓度与毒性之间的关系。
